Tango Therapeutics, Inc. (TNGX) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Tango Therapeutics, Inc. is a precision oncology company focused on developing novel small molecules targeting tumor suppressor gene loss. The company has no products approved for commercial sale and has not generated revenue from product sales. As of May 5, 2025, there were 108,394,190 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Collaboration Revenue | $5.4 million | $6.5 million |
| Net Loss | $(39.9) million | $(37.9) million |
| Net Loss Per Share (Basic & Diluted) | $(0.36) | $(0.35) |
| Research & Development Expenses | $36.4 million | $38.1 million |
| General & Administrative Expenses | $11.5 million | $10.7 million |
| Cash, Cash Equivalents & Marketable Securities | $216.7 million | $213.4 million (Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(41.7) million | $(37.9) million |
| Accumulated Deficit | $(541.4) million | $(409.2) million (Mar 31, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $1.1 million (17%) compared to Q1 2024. This reduction is attributed to lower research costs incurred under the Gilead collaboration agreement during the period.
- R&D Expense Reduction: Total R&D expenses decreased by $1.6 million. This was primarily driven by a $5.8 million reduction due to the discontinuation of the TNG908 (stopped enrollment Nov 2024) and TNG348 (discontinued May 2024) clinical programs.
- New Program Costs: The decrease in discontinued programs was partially offset by a $3.5 million increase in expenses for new programs TNG961 and TNG456, and a $1.1 million increase in personnel-related costs.
- Interest Income: Interest income decreased by $0.6 million to $1.6 million, reflecting a lower balance of marketable securities compared to the prior year.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($216.7 million) to fund operations into the first quarter of 2027.
- TNG462: Enrolling in Phase 1/2 monotherapy trial; clinical data update expected in H2 2025. A combination trial with Revolution Medicines' RAS(ON) inhibitors is expected to begin enrollment in Q2 2025.
- TNG456: FDA cleared the IND in January 2025. Phase 1/2 trial for GBM is planned to begin enrollment in Q2 2025.
- TNG260: Enrolling in dose expansion; clinical data expected in H2 2025.
Risks and Contingencies:
- Regulatory & Political Risk: The filing highlights risks associated with potential government shutdowns, funding cuts to the FDA/SEC, and policy changes under the new U.S. presidential administration (Trump administration), which could delay regulatory reviews.
- Supply Chain Risk: The company relies on a single source (an affiliate of WuXi AppTec) for the active pharmaceutical ingredients (API) for all clinical-stage candidates. Proposed Congressional legislation could restrict business with WuXi AppTec.
- Development Risk: The company has never successfully completed a clinical trial. Discontinuation of TNG908 and TNG348 underscores the uncertainty of clinical development.
Investor Verification Checklist
- Verify the specific timeline for the TNG462 combination trial enrollment and the H2 2025 data readout dates.
- Monitor legislative developments regarding WuXi AppTec and potential impacts on Tango's API supply chain.
- Track the burn rate relative to the stated Q1 2027 cash runway, particularly as new trials (TNG456, TNG462 combo) ramp up.
- Review the status of the Gilead collaboration revenue recognition schedule and remaining deferred revenue ($57.0 million total).
- Assess the impact of potential FDA staffing or policy changes on the IND clearance and trial approval process for TNG456.